Kura Oncology Inc (NAS:KURA)
$ 8.86 -0.08 (-0.89%) Market Cap: 688.99 Mil Enterprise Value: 250.32 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 29/100

Kura Oncology Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 11, 2020 / 03:15PM GMT
Release Date Price: $39.38 (+0.15%)
Martin Douglas Auster;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

Okay. Well. Welcome, everybody. I'm Marty Auster. I'm the lead SMID Cap Biotech Analyst at Crédit Suisse. Thanks for joining us again at the 29th Annual Credit Suisse Healthcare Conference.

Up next, we've got Kura oncology. I've got Troy Wilson, President and CEO of the company, to make a presentation on Kura Oncology. We'll be conducting maybe a brief Q&A at the end, time allowing. If anybody in the audience has any questions, please shoot me an e-mail, and I'll work those into the -- to that brief Q&A session at the end of the presentation.

Troy, let me hand it over to you. Thanks for joining us today.

Troy Edward Wilson
Kura Oncology, Inc. - Chairman, CEO & President

Thank you, Marty, and thanks to you and Crédit Suisse for the invitation to participate in your conference. Good morning, everyone. Today, I'll be giving an overview of Kura Oncology and the progress that we're making in advancing our 2 wholly owned assets

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot